Silo Pharma (SILO) Stock Price, News & Analysis

Company Overview

Silo Pharma, Inc. (NASDAQ:SILO) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel psychedelic and related synthetic therapies. Headquartered in New York City, the company applies proprietary chemistry and targeted drug delivery approaches to advance candidates that address critical unmet needs across oncology, neurology and mental health.

The company’s preclinical and early-stage clinical pipeline comprises several programs that explore serotonin receptor modulators, synthetic analogs of classic psychoactive compounds and neuroprotective agents. Key initiatives include research into treatments for chemotherapy-induced neurotoxicity, glioblastoma, neurodegenerative disorders and mood conditions such as depression and post-traumatic stress disorder. Silo Pharma leverages strategic collaborations and material licensing agreements with leading academic institutions to accelerate its research efforts.

Originally founded as Elicio Therapeutics in 2019, the firm rebranded to Silo Pharma in 2021 to underscore its specialized focus on psychedelics and novel CNS therapies. In addition to its U.S. operations, the company engages in collaborative research activities with partners in Canada and Europe. Silo Pharma’s leadership team brings together expertise in pharmaceutical R&D, regulatory strategy and business development to position the company for growth in the emerging psychedelics sector.

Key Stats

• Today's Range: $5.50 to $6.35
• 50-Day Range: $4.99 to $10.05
• 52-Week Range: $3.32 to $15.15
• Volume: 52,753 shs
• Average Volume: 25,894 shs
• Market Capitalization: $5.74 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Sell

Silo Pharma Stock Analysis - MarketRank™

Silo Pharma scored higher than 10% of companies evaluated by MarketBeat, and ranked 839th out of 865 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 0.7 / 5
• Analyst Rating: Sell

Consensus Rating

Silo Pharma has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.

Amount of Analyst Coverage

Silo Pharma has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Silo Pharma is -14.21, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Silo Pharma is -14.21, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Silo Pharma has a P/B Ratio of 13.00. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

4.58% of the float of Silo Pharma has been sold short.

Short Interest Ratio / Days to Cover

Silo Pharma has a short interest ratio ("days to cover") of 2.46, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Silo Pharma has recently decreased by 5.72%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Silo Pharma does not currently pay a dividend.

Dividend Growth

Silo Pharma does not have a long track record of dividend growth.

News and Social Media

• Score: 1.9 / 5
• News Sentiment: -0.02

News Sentiment

Silo Pharma has a news sentiment score of -0.02. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.81 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 4 news articles for Silo Pharma this week, compared to 2 articles on an average week.

MarketBeat Follows

7 people have added Silo Pharma to their MarketBeat watchlist in the last 30 days. This is an increase of 600% compared to the previous 30 days.

Company Ownership

• Score: 0.1 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Silo Pharma insiders have not sold or bought any company stock.

Percentage Held by Insiders

2.22% of the stock of Silo Pharma is held by insiders.

Percentage Held by Institutions

5.58% of the stock of Silo Pharma is held by institutions.

Company Calendar

• Last Earnings: 3/27/2026
• Today: 6/04/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Apparel
• Current Symbol: NASDAQ:SILO
• CIK: 1514183
• Web: silopharma.com
• Phone: (718) 400-9031
• Fax: N/A
• Employees: 2
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): ($0.43)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$4.23 million
• Net Margins: -6,726.39%
• Pretax Margin: -6,727.78%
• Return on Equity: -88.40%
• Return on Assets: -70.03%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 9.65
• Quick Ratio: 9.65

Sales & Book Value

• Annual Sales: $70 thousand
• Price / Sales: 82.05
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $7.10 per share
• Price / Book: 0.86

Miscellaneous

• Outstanding Shares: 940,000
• Free Float: 924,000
• Market Cap: $5.74 million
• Optionable: Not Optionable
• Beta: 0.63